



Published in final edited form as:

Am J Cardiol. 2022 November 15; 183: 122–128. doi:10.1016/j.amjcard.2022.08.006.

Association of Left Atrial Structure and Function with Cognitive Function Among Adults with the Metabolic Syndrome

Ines Gonzalez Casanova, PhD¹, Ángel M. Alonso-Gómez, MD, PhD^{2,3}, Dora Romaguera, PhD^{3,4}, Estefanía Toledo, MD, PhD^{3,5,6}, Elena Fortuny, MD, PhD^{4,7}, Luis López, MD⁸, Raúl Ramallal, MD, PhD^{6,9}, Jordi Salas-Salvadó, PhD^{3,10,11}, Lucas Tojal-Sierra, MD^{2,3}, Olga Castañer, MD, PhD^{3,12}, Alvaro Alonso, MD, PhD¹³

¹Department of Applied Health Science, Indiana University Bloomington School of Public Health, Bloomington, IN, USA

²Bioaraba Health Research Institute; Osakidetza Basque Health Service, Araba University Hospital; University of the Basque Country UPV/EHU; Vitoria-Gasteiz, Spain

³CIBER Consortium, M.P. Physiopathology of Obesity and Nutrition (CIBEROBn), Carlos III Health Institute (ISCIII), Madrid, Spain.

⁴Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain.

⁵Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain

⁶IdiSNA, Navarra Institute for Health Research, Pamplona, Spain

⁷Cardiology Service, Manacor Hospital, Palma de Mallorca, Spain

⁸Cardiology Service, Son Espases University Hospital, Palma de Mallorca, Spain

⁹Department of Cardiology, University Hospital of Navarra, Servicio Navarro de Salud Osasunbidea, Pamplona, Spain

¹⁰Universitat Rovira i Virgili, Department of Biochemistry and Biotechnology, Human Nutrition Unit, Reus, Spain

¹¹Institut d'Investigació Sanitària Pere Virgili (IISPV), Human Nutrition Unit, Reus, Spain.

¹²Cardiovascular risk and nutrition research group, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain

¹³Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA

Abstract

Atrial fibrillation (AF) has been associated with cognitive impairment. Whether subclinical abnormalities in atrial function and substrate predisposing to AF impact cognitive function has received limited attention. We tested associations of echocardiographic markers of atrial structure and function with cognitive functioning and decline among 510 participants with overweight/

obesity and metabolic syndrome (mean age [standard deviation] of 64.4 [5.2] years in men and 66.5 [3.9] in women). Left atrial (LA) markers (volume index, emptying fraction, strain, function index, and stiffness index) were estimated based on transthoracic echocardiography. General cognitive functioning (Mini-mental examination), verbal ability (verbal fluency test), memory and attention (Digit Span Tests), and processing speed and executive function (Trail-Making Tests A and B) were assessed at baseline and at the 2-year follow-up. Multiple linear regression was used to test associations of atrial markers (modeled in standard deviation units) with baseline and 2-year changes in cognitive scores adjusting for demographic and health covariates. LA structure and function were not associated with cognitive function at baseline. Larger LA volume index (standardized β [95% confidence interval] = -0.13 [$-0.22, -0.03$]), lower peak longitudinal strain (-0.11 [$-0.20, -0.01$]), and higher stiffness index (-0.18 [$-0.28, -0.08$]) were associated with 2-year worsening in Trail-Making Test A. Strain measurements were also associated with 2-year change in the Controlled Oral Word Association Test. In conclusion, overall, adverse markers of LA structure and function were associated with 2-year detrimental executive function-related cognitive changes in a sample of participants at high risk for cardiovascular disease, highlighting LA substrate as a potential risk factor for cognitive decline and dementia.

Keywords

left atrial structure; left atrial function; cognitive decline; atrial fibrillation; cognitive function; aging

Introduction

Atrial fibrillation (AF), a common cardiac arrhythmia associated with high risk of cardiovascular events, has been identified as an important risk factor for age-related mild cognitive decline and dementia.^{1,2} Specific causal pathways potentially responsible for this association include increased risk of cerebral infarcts, microhemorrhages and cerebral hypoperfusion in people with AF.³ Moreover, the increased risk of cognitive impairment in AF might be a consequence of abnormalities in the atrial structural and functional substrate, independently of the presence of the arrhythmia.⁴ Prior studies suggest that LA abnormalities identified through electrocardiogram are associated with an increased risk of dementia independently of AF.⁵ Similarly, LA volume has been associated with cognitive decline in older adults.⁶ The association of echocardiographic markers of LA function with cognitive function and dementia, however, has received limited attention. Therefore, the objective of this analysis was to assess whether markers of LA structure and function, which provide the AF substrate, were associated with cognitive function and cognitive decline among overweight or obese adults with metabolic syndrome participating in the PREDIMED-PLUS randomized trial.

Methods

The PREDIMED-PLUS trial is an ongoing multicenter randomized controlled trial aimed at preventing cardiovascular disease in overweight or obese adults with metabolic syndrome (ISRCTN89898870). Recruitment started in 2013 and included 3,574 men (age 55–75

y) and 3,300 women (age 60–75 y). Participants were recruited in 23 centers in Spain and randomized 1:1 to an intensive lifestyle intervention (ILI) program based on an energy-restricted Mediterranean diet, increased physical activity, and cognitive-behavioral weight management or to a control intervention of low-intensity dietary advice on the Mediterranean diet (not energy-restricted).⁷

Inclusion criteria for the PREDIMED-PLUS trial were men aged 55–75 years and women aged 60–75 years, with overweight or obesity (body mass index 27–40 kg/m²), who at baseline met at least three components of the metabolic syndrome. Exclusion criteria have been described elsewhere and included uncontrolled AF and documented history of other cardiovascular diseases among others.⁸

For this analysis, we included a sub-sample of 510 PREDIMED-PLUS participants from three recruiting centers (University of Navarra, Araba University Hospital, Son Espases University Hospital) who underwent transthoracic echocardiography at baseline and who also had information on at least one cognitive test at baseline or at the two-year follow-up.

Study protocols were approved by Institutional Review Boards at all participating institutions. All participants provided written informed consent.

At baseline and at the two-year follow-up visit, participants underwent a detailed cognitive assessment evaluating different domains. The Mini-mental state examination (MMSE)^{9,10} test was validated in Spanish population to assess general cognitive impairment. It is a 30-point questionnaire that produces sub-scales for time and spatial orientation, immediate and deferred recall, attention, calculation, and language. These scores are added to produce the overall MMSE score, where a threshold of less than 24 is defined as cognitive impairment.¹¹ We used the Spanish version of the Digit Span Test¹² that is part of the Wechsler Adult Intelligence Scale battery.¹³ It has a forward component that measures short-term memory and attention, and a backward component that measures working memory. In the forward test, participants are requested to repeat a series of random single digits in the order they heard them, and in the backward test, they are requested to repeat a series of numbers in the inverse of the order they heard them. Semantic and phonetic fluency were respectively evaluated by asking participants to mention as many animals or words containing the letter “P” as possible in 60 seconds.¹⁴ Finally, the Trail Making Test¹⁵ measures processing speed and executive function. The Trail Making Test A, where participants are asked to connect numbers 1 to 25 in the correct order, is meant to assess cognitive processing skills. The task B consists of connecting numbers and letters alternatively in the correct order.

Participants from three sites were invited to undergo transthoracic echocardiography following a common protocol. Echocardiographic examinations were performed at baseline using an ultrasound scanner Vivid 7 or Vivid 9 (General Electric Healthcare). M-mode, doppler imaging and two-dimensional cine loops for 3 heart beats of standards views were obtained from each patient. All images were then digitally stored. The offline ultrasound software EchoPac (V.203; revision 59.0; GE Healthcare) was used for image analysis and measurements. For reliability purposes, images were read at a core reading center (Son Espases University Hospital) by two trained readers blind to clinical data following

recommendations of the American Society of Echocardiography.¹⁶ Markers of LA structure included the LA volume index (LA volume indexed to body surface area), while markers of LA function included the LA emptying fraction, the peak LA longitudinal strain, conduit strain, and contractile strain, the LA function index, and the LA stiffness index. LA emptying fraction was calculated as $(V_{max} - V_{min})/V_{max}$, where V_{max} is the maximum volume of the LA just before the opening of the mitral valve and V_{min} is the minimal volume at the closure of the mitral valve. LA emptying fraction is a measure of the LA volumetric function. The peak LA longitudinal strain, a marker of LA myocardial function, was measured at the end of the reservoir phase. The conduit and contractile strains relate to LA function during the diastole: early diastole strain represents conduit function and late diastole strain represents contractile function. The LA function index combines the reservoir function, the adjusted LA volume, and the stroke volume to reflect left ventricular systolic and diastolic function. It was calculated as (LA emptying fraction \times left ventricular outflow tract-velocity time integral) / indexed LA end-systolic volume.¹⁷ The LA stiffness index, a measure of LA remodeling and fibrosis, was calculated as E/e' ratio divided by peak LA systolic longitudinal strain, where E represents the early mitral inflow velocity (E wave) and e' represents the medial and lateral mitral annular velocity.¹⁸

Participants' sociodemographic and health characteristics were assessed at baseline via a face-to-face questionnaire. Sociodemographic variables included age at baseline, sex, marital status (single or married), education (years of schooling), occupation (employed, unemployed, retired, housework) and recruitment site (Mallorca, Vitoria, or Navarra). Body mass index was measured at baseline and included in the analysis, as well as self-reported history of diabetes, hypertension, depression, or non-AF arrhythmia. CHA₂DS₂-VASc score was calculated using baseline information and was used as a descriptive variable.¹⁹

We first conducted exploratory analyses by testing bi-variate unadjusted associations between markers of LA structure and function and cognitive scores at baseline, as well as associations with baseline sociodemographic variables. LA structure and function variables were scaled in standard deviation units to facilitate comparisons across variables. For LA conduit and contractile strain, we used the absolute value instead of the negative percentage to keep the direction of our estimates consistent with peak LA longitudinal strain estimates. All cognitive functioning scores were standardized to a mean of 0 and a standard deviation of 1 using the mean and standard deviation of the sample. With the exception of the Trail Making Test, lower values of the cognitive tests reflect worse cognitive function. To ensure consistency in the interpretation of results, the analyses used the additive inverse of Trail Making Tests score [-(Trail Making Test)] where lower values in this test indicate worse test performance.

Multivariable linear models were used to test cross-sectional associations between markers of LA structure and function and cognitive functioning outcomes at baseline. We ran models adjusted only for age, sex and site, and then fully adjusted for sociodemographic characteristics (marital status, years of schooling, employment), medical history (diabetes, hypertension, minor arrhythmias, depression), body mass index, and smoking (categorized into current, former, or never smoker), 17-item Mediterranean Diet score,²⁰ and METs per day of moderate to vigorous physical activity estimated using the long version of

the Minnesota leisure time physical activity questionnaire.²¹ Estimates where the 95% confidence interval did not cross the null in both partially and fully adjusted models were considered significant.

The difference between cognitive function scores at baseline and at the 2-year follow-up was calculated by subtracting the former from the latter. Multiple linear regression was used to test the association between LA structure and function and this difference using a similar modeling approach that was additionally adjusted for intervention arm as a potential confounder. Sensitivity analyses were performed after excluding participants that were born outside of Spain (n=20) because Spanish may not be their first language and those with evidence of AF in their baseline ECG (n=12). An additional sensitivity analysis excluding those with MMSE <24 had been planned but none of the participants had values below this cutoff.

Results

There were 510 participants included in the analyses, of which 468 (92%) had a repeated cognitive assessment two years later (Figure 1). Participants were on average 65 years at baseline, and majority male. Men were significantly more likely to smoke or be former smokers than women and were more physically active. Women had fewer years of schooling and were more likely to have depression (Table 1). Small average 2-year decreases were found for semantic fluency, digit span and the trail making tests A and B; these negative differences were greater among men (Table 2).

At baseline, none of the LA structural and functional substrate markers were cross-sectionally associated with cognitive functioning tests (Table 3). Among 468 participants with repeated cognitive assessment included in the longitudinal analysis, however, higher LA peak systolic longitudinal strain was associated with more favorable 2-year changes in the Digits Span Test and Trail Making Test A. (Table 4). Larger LA volume index and higher LA stiffness index were both associated with more decline in Trail Making Test A. An inverse association was observed between conduit strain and phonetic fluency, with higher absolute conduit strain associated with larger declines in phonetic fluency (-0.10, 95% CI -0.17, -0.02) (Table 4). The sensitivity test excluding foreign born participants and those with baseline AF did not modify the results.

Discussion

Previous studies have shown associations between cardiovascular risk in general or AF in particular, and cognitive decline or dementia.^{2,22,23} The aim of this study was to test associations between markers of LA remodeling, which are associated with AF, and cognitive function and change in a sample of overweight adults with no cardiovascular disease or dementia. We found no associations of markers of LA structure and function (volume, emptying fraction, strain, function index, and stiffness index) with various measurements of cognitive function at baseline. We did, however, find some associations between markers of favorable LA volume and function (lower LA volume index, higher LA peak longitudinal strain, lower LA stiffness index) and more favorable 2-year changes in

scores of tests related to executive function (Trail Making Test A, Digits Span Test) among this subsample of participants of the PREDIMED-PLUS intervention study.

A large body of evidence supports an association between AF and cognitive decline. In turn, measures of LA structure and function, which characterize the LA substrate of AF, have been associated with increased risk of AF and cardiovascular disease.²⁴ Less evidence is available of the potential impact of the AF substrate on cognitive function, although some studies have suggested that even subclinical cardiac dysfunction and markers of AF risk could be associated with cognitive decline in older adults.^{5,25,26}

Left atrial volume index has been widely used as a marker of cardiac structural health, where higher values (LA enlargement) predict worse cardiovascular outcomes.²⁷ Prior work has also evaluated the association of LA volume with cognitive outcomes. A previous study found associations between LA volume index and cognitive impairment defined using a cutoff of <25 in the Mini-mental examination in older adults.⁶ However, a more recent study found that LA enlargement measured by volume index >34 was not associated with 5-year decline in a composite cognitive score.²⁸ In our analysis, we found an inverse association between LA volume index and 2-year decline in the Trail Making Test A, but not in the Mini Mental Examination or in other domains. This is a sample of participants with no severe cognitive impairment at baseline (based on the trial exclusion criteria) and with a shorter follow-up. It is possible that the Trail Making Test is more sensitive to small changes related to subclinical alterations in volume and function because it measures executive functioning and has been directly linked to activity in the prefrontal cortex.²⁹

Peak atrial longitudinal strain is a measure of LA function, where lower values reflect impaired reservoir function. We found that higher peak LA longitudinal strain was associated with less decline in executive function, specifically in the Trail-Making Test A. Conversely, conduit strain, a subcomponent of the longitudinal strain and a marker of LA conduit function, was inversely associated with phonetic scores. The direction of this finding is inconsistent with the LA longitudinal strain results, making us cautious in the overall interpretation of the results.

Left atrial stiffness index is a marker of atrial remodeling and indicates deteriorated reservoir function. It is calculated non-invasively as the quotient of the E/e' ratio and the LA peak longitudinal strain³⁰. In our study, it was associated with worse decline in the Trail Making Test A, a measure of executive function. To our knowledge this is the first study to find associations between this index and cognitive function, and further research is necessary to confirm this association. We should also consider multiple testing when interpreting our results. Among many tests conducted, even if most of them were consistent in terms of direction of association and magnitude of effect, only a few reached the traditional threshold of statistical significance, raising concerns that some or all could be chance findings due to multiple testing. Hence, while the results contribute to the general body of evidence in the field, they require confirmation in separate studies.

Strengths of the study include the careful assessment of LA structure and function using echocardiography, the relatively large sample size, the excellent retention of study

participants over time, the various measurements of different aspects of cognitive function and repeated measurements that allowed assessing differences over time, and information on a wide range of covariates. Conversely, a limitation is that the PREDIMED-PLUS trial excluded people with cardiovascular disease or severe cognitive functioning from enrollment, which may have limited our ability to study a higher-risk population and may have affected the baseline analyses. Also, information on incident AF during follow-up was not considered, since AF is a secondary endpoint for the trial and not available yet. Another limitation of our study is that cognitive function was only available at two time points and that the follow-up time between the assessments was only 2 years. Finally, the study did not obtain brain imaging, which may allow a more detailed examination of this question. Future studies should assess the association between AF substrate and cognition among populations with higher prevalence of AF and wider variation on cognitive function, as well as the association with cognitive decline after longer follow-ups.

In conclusion, better LA structure and function were associated with lower decline in cognitive tests reflecting the areas of memory and executive function in individuals at high risk of cardiovascular disease, highlighting the importance of the LA substrate as a potential risk factor for cognitive decline and dementia.

Funding

Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Numbers R01HL137338 and K24HL148521, and administrative supplement to promote diversity 3R01HL137338-03S1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The PREDIMED-Plus trial was supported by the official funding agency for biomedical research of the Spanish government, ISCIII, through the Fondo de Investigación para la Salud (FIS), which is co-funded by the European Regional Development Fund (PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/0147, PI14/00636, PI14/00972, PI14/00618, PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926, PI19/00957, PI19/00386, PI19/00309, PI19/01032, PI19/00576, PI19/00017, PI19/01226, PI19/00781, PI19/01560, PI19/01332, PI20/01802, PI20/00138, PI20/01532, PI20/00456, PI20/00339, PI20/00557, PI20/00886, PI20/01158), the European Research Council Advanced Research Grant 2013–2018 (340918), the Recercaixa grant 2013ACUP00194, grants from the Consejería de Salud de la Junta de Andalucía (PI0458/2013; PS0358/2016, PI0137/2018), the PROMETEO/2017/017 grant from the Generalitat Valenciana, the SEMERGEN grant and FEDER funds (CB06/03). JS-S, is partially supported by ICREA under the ICREA Academia program. None of the funding sources took part in the design, collection, analysis, interpretation of the data, or writing the report, or in the decision to submit the manuscript for publication.

References

1. Santangeli P, Di Biase L, Bai R, Mohanty S, Pump A, Cereceda Brantes M, Horton R, Burkhardt JD, Lakkireddy D, Reddy YM, Casella M, Dello Russo A, Tondo C, Natale A. Atrial fibrillation and the risk of incident dementia: A meta-analysis. *Heart Rhythm* 2012;9:1761–1768.e1762. [PubMed: 22863685]
2. Islam MM, Poly TN, Walther BA, Yang H-C, Wu CC, Lin M-C, Chien S-C, Li Y-C. Association Between Atrial Fibrillation and Dementia: A Meta-Analysis. *Front Aging Neurosci* 2019;11:305–305. [PubMed: 31780919]
3. Madhavan M, Graff-Radford J, Piccini JP, Gersh BJ. Cognitive dysfunction in atrial fibrillation. *Nature Reviews Cardiology* 2018;15:744–756. [PubMed: 30275499]
4. Alonso A, Arenas de Larriva AP. Atrial Fibrillation, Cognitive Decline And Dementia. *Eur Cardiol* 2016;11:49–53. [PubMed: 27547248]

5. Gutierrez A, Norby FL, Maheshwari A, Rooney MR, Gottesman RF, Mosley TH, Lutsey PL, Oldenburg N, Soliman EZ, Alonso A, Chen LY. Association of Abnormal P-Wave Indices With Dementia and Cognitive Decline Over 25 Years: ARIC-NCS (The Atherosclerosis Risk in Communities Neurocognitive Study). *J Am Heart Assoc* 2019;8:e014553. [PubMed: 31830872]
6. Karadag B, Ozyigit T, Ozben B, Kayaoglu S, Altuntas Y. Relationship between left atrial volume index and cognitive decline in elderly patients with sinus rhythm. *J Clin Neurosci* 2013;20:1074–1078. [PubMed: 23685105]
7. Martínez-González MA, Buil-Cosiales P, Corella D, Bulló M, Fitó M, Vioque J, Romaguera D, Martínez JA, Wärnberg J, López-Miranda J, Estruch R, Bueno-Cavanillas A, Arós F, Tur JA, Tinahones F, Serra-Majem L, Martín V, Lapetra J, Vázquez C, Pintó X, Vidal J, Daimiel L, Delgado-Rodríguez M, Matía P, Ros E, Fernández-Aranda F, Botella C, Portillo MP, Lamuela-Raventós RM, Marcos A, Sáez G, Gómez-Gracia E, Ruiz-Canela M, Toledo E, Alvarez-Alvarez I, Díez-Espino J, Sorlí JV, Basora J, Castañer O, Schröder H, Navarrete-Muñoz EM, Zulet MA, García-Rios A, Salas-Salvadó J. Cohort Profile: Design and methods of the PREDIMED-Plus randomized trial. *Int J Epidemiol* 2018;48:387–388o.
8. Martínez-González MA, Buil-Cosiales P, Corella D, Bulló M, Fitó M, Vioque J, Romaguera D, Martínez JA, Wärnberg J, López-Miranda J, Estruch R, Bueno-Cavanillas A, Arós F, Tur JA, Tinahones F, Serra-Majem L, Martín V, Lapetra J, Vázquez C, Pintó X, Vidal J, Daimiel L, Delgado-Rodríguez M, Matía P, Ros E, Fernández-Aranda F, Botella C, Portillo MP, Lamuela-Raventós RM, Marcos A, Sáez G, Gómez-Gracia E, Ruiz-Canela M, Toledo E, Alvarez-Alvarez I, Díez-Espino J, Sorlí JV, Basora J, Castañer O, Schröder H, Navarrete-Muñoz EM, Zulet MA, García-Rios A, Salas-Salvadó J. Cohort Profile: Design and methods of the PREDIMED-Plus randomized trial. *International journal of epidemiology* 2019;48:387–388o. [PubMed: 30476123]
9. Upton J Mini-Mental State Examination. In: Gellman MD, Turner JR, eds. *Encyclopedia of Behavioral Medicine*. New York, NY: Springer New York, 2013:1248–1249.
10. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975;12:189–198. [PubMed: 1202204]
11. Mitchell AJ. A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. *J Psychiatr Res* 2009;43:411–431. [PubMed: 18579155]
12. Wambach D, Lamar M, Swenson R, Penney DL, Kaplan E, Libon DJ. Digit Span. In: Kreutzer JS, DeLuca J, Caplan B, eds. *Encyclopedia of Clinical Neuropsychology*. New York, NY: Springer New York, 2011:844–849.
13. Wechsler D WAIS-III, escala de inteligencia de Wechsler para adultos-III : manual de aplicación y corrección. Madrid: TEA, 2001.
14. Patterson J Controlled Oral Word Association Test. In: Kreutzer JS, DeLuca J, Caplan B, eds. *Encyclopedia of Clinical Neuropsychology*. New York, NY: Springer New York, 2011:703–706.
15. Llinàs-Reglà J, Vilalta-Franch J, López-Pousa S, Calvó-Perxas L, Torrents Rodas D, Garre-Olmo J. The Trail Making Test. *Assessment* 2017;24:183–196. [PubMed: 26318386]
16. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2016;29:277–314. [PubMed: 27037982]
17. Thomas L, Hoy M, Byth K, Schiller NB. The left atrial function index: a rhythm independent marker of atrial function. *European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology* 2008;9:356–362. [PubMed: 17689293]
18. Machino-Ohtsuka T, Seo Y, Tada H, Ishizu T, Machino T, Yamasaki H, Igarashi M, Xu D, Sekiguchi Y, Aonuma K. Left atrial stiffness relates to left ventricular diastolic dysfunction and recurrence after pulmonary vein isolation for atrial fibrillation. *Journal of cardiovascular electrophysiology* 2011;22:999–1006. [PubMed: 21457382]
19. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based

- approach: the euro heart survey on atrial fibrillation. *Chest* 2010;137:263–272. [PubMed: 19762550]
20. Sofi F, Macchi C, Abbate R, Gensini GF, Casini A. Mediterranean diet and health status: an updated meta-analysis and a proposal for a literature-based adherence score. *Public Health Nutrition* 2014;17:2769–2782. [PubMed: 24476641]
 21. Elosua R, Marrugat J, Molina L, Pons S, Pujol E. Validation of the Minnesota Leisure Time Physical Activity Questionnaire in Spanish Men. *American Journal of Epidemiology* 1994;139:1197–1209. [PubMed: 8209878]
 22. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta-analysis. *Ann Intern Med* 2013;158:338–346. [PubMed: 23460057]
 23. Song R, Xu H, Dintica CS, Pan K-Y, Qi X, Buchman AS, Bennett DA, Xu W. Associations Between Cardiovascular Risk, Structural Brain Changes, and Cognitive Decline. *J Am Coll Cardiol* 2020;75:2525–2534. [PubMed: 32439001]
 24. Szegedi I, Szapáry L, Csécei P, Csanádi Z, Csiba L. Potential Biological Markers of Atrial Fibrillation: A Chance to Prevent Cryptogenic Stroke. *Biomed Res Int* 2017;2017:8153024–8153024. [PubMed: 28785588]
 25. Russo C, Jin Z, Liu R, Iwata S, Tugcu A, Yoshita M, Homma S, Elkind MSV, Rundek T, Decarli C, Wright CB, Sacco RL, Di Tullio MR. LA volumes and reservoir function are associated with subclinical cerebrovascular disease: the CABL (Cardiovascular Abnormalities and Brain Lesions) study. *JACC Cardiovasc Imaging* 2013;6:313–323. [PubMed: 23473112]
 26. Kresge HA, Khan OA, Wagener MA, Liu D, Terry JG, Nair S, Cambronero FE, Gifford KA, Osborn KE, Hohman TJ, Pechman KR, Bell SP, Wang TJ, Carr JJ, Jefferson AL. Subclinical Compromise in Cardiac Strain Relates to Lower Cognitive Performances in Older Adults. *J Am Heart Assoc* 2018;7:e007562. [PubMed: 29440034]
 27. Tsang TS, Abhayaratna WP, Barnes ME, Miyasaka Y, Gersh BJ, Bailey KR, Cha SS, Seward JB. Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? *Journal of the American College of Cardiology* 2006;47:1018–1023. [PubMed: 16516087]
 28. Zhang MJ, Norby FL, Lutsey PL, Mosley TH, Cogswell RJ, Konety SH, Chao TF, Shah AM, Solomon SD, Alonso A, Chen LY. Association of Left Atrial Enlargement and Atrial Fibrillation With Cognitive Function and Decline: The ARIC-NCS. *J Am Heart Assoc* 2019;8:e013197. [PubMed: 31766970]
 29. Shibuya-Tayoshi S, Sumitani S, Kikuchi K, Tanaka T, Tayoshi SY, Ueno S-I, Ohmori T. Activation of the prefrontal cortex during the Trail-Making Test detected with multichannel near-infrared spectroscopy. *Psychiatry and Clinical Neurosciences* 2007;61:616–621. [PubMed: 18081621]
 30. Machino-Ohtsuka T, Seo Y, Tada H, Ishizu T, Machino T, Yamasaki H, Igarashi M, Xu D, Sekiguchi Y, Aonuma K. Left atrial stiffness relates to left ventricular diastolic dysfunction and recurrence after pulmonary vein isolation for atrial fibrillation. *J Cardiovasc Electrophysiol* 2011;22:999–1006. [PubMed: 21457382]




Figure 1.
Flowchart of participants included for this analysis

Table 1:

Baseline characteristics of participants included in the analysis

Variable (% or mean (SD))	Male (307)	Female (203)	Total (510)
Site			
Mallorca (%)	24.1	36.5	29.0
Navarra (%)	19.5	18.7	19.2
Vitoria (%)	56.3	44.8	51.8
Age (years)	64.4 (5.2)	66.5 (3.9)	65.1 (4.8)
Married (%)	85.0	65.5	77.3
People living in the household	1.4 (1.0)	1.1 (0.9)	1.3 (1.0)
Schooling (years)	13.0 (5.5)	10.4 (4.4)	12.0 (5.3)
Employed (%)	21.5	9.9	16.9
Health status			
Body Mass Index (kg/m ²)	32.4 (3.1)	32.9 (3.6)	32.6 (3.3)
Type 2 Diabetes (%)	22.8	25.1	23.7
Hypertension (%)	84.4	81.8	83.2
Depression (%)	13.0	28.1	19.0
Arrhythmia (%)	5.9	5.9	5.9
Antiplatelet or Anticoagulant medication (%)	4.6	0.5	3.0
CHA ₂ DS ₂ -VASc Score for Atrial Fibrillation	1.6 (0.8)	2.8 (0.9)	2.1 (1.0)
Stroke Risk			
Smoker (%)	10.8	7.2	9.4
Former Smoker (%)	66.8	29.1	51.8
Mediterranean Diet Score	7.2 (2.7)	8.0 (3.0)	7.5 (2.9)
Moderate to vigorous physical activity (METs/day)	332.9 (360.6)	173.5 (213.0)	269.4 (319.8)
General Echocardiographic Measures			
Left Ventricle Mean Ejection Fraction (%)	64.9 (6.3)	66.1 (7.9)	65.4 (7.0)
Left Atrial Substrate			
Volume Index (mL/m ²)	23.3 (7.2)	23.1 (8.2)	23.2 (7.6)
Emptying Fraction (%)	58.6 (17.8)	55.9 (10.0)	57.5 (15.2)
Peak Systolic Longitudinal Strain (%)	27.8 (6.9)	26.4 (6.6)	27.2 (6.8)
Conduit Strain (%)	-12.2 (4.2)	-11.5 (4.6)	-11.9 (4.4)
Contractile Strain (%)	-15.7 (5.3)	-14.8 (4.6)	-15.3 (5.2)
Function Index (U)	64.3 (41.0)	66.2 (28.8)	65.1 (36.6)
Stiffness Index (U)	0.3 (0.2)	0.4 (0.2)	0.4 (0.2)

Cognitive function at baseline and 2-year difference among 510 participants of the PREDIMED-PLUS study

Table 2:

Cognitive Function Measurement (mean (standard deviation))	Males (n=307)	Females (n=203)	Total (n=510)
Mini-mental examination (score)			
Baseline	28.8 (1.6)	28.1 (2.1)	28.5 (1.9)
2-year difference	-0.1 (1.5)	0.1 (1.9)	-0.0 (1.7)
Semantic Fluency (score)			
Baseline	17.3 (5.4)	15.1 (4.6)	16.4 (5.2)
2-year difference	-0.6 (4.7)	-0.3 (4.0)	-0.5 (4.4)
Phonetic Fluency (score)			
Baseline	12.6 (4.5)	11.1 (4.1)	12.0 (4.4)
2-year difference	0.1 (3.7)	0.6 (3.5)	0.3 (3.6)
Digits span total (score)			
Baseline	14.2 (3.6)	12.1 (3.1)	13.4 (4.0)
2-year difference	-0.3 (2.8)	0.0 (2.2)	-0.2 (2.6)
Trail Making Test A (seconds)			
Baseline	43.9 (17)	54.2 (24.5)	48.0 (4.0)
2-year difference	2.6 (15.8)	0.7 (27.4)	1.8 (21.1)
Trail Making Test B (seconds)			
Baseline	111.0 (62.7)	145.6 (79.1)	124.7 (71.6)
2-year difference	6.4 (50.6)	5.5 (60.7)	6.1 (54.7)

Table 3: Association of left atrium structure and function with baseline cognitive function scores among 510 participants of the PREDIMED-PLUS Trial

Left atrial measurements	Mini-mental examination	Semantic fluency	Phonetic fluency	Digits span total (n=389)	Trail Making Test A	Trail Making Test B	
Volume Index	Model 1	-0.03 (-0.12, 0.06)	0.06 (-0.03, 0.15)	-0.03 (-0.13, 0.06)	0.01 (-0.09, 0.10)	0.07 (-0.02, 0.15)	0.02 (-0.06, 0.11)
	Model 2	-0.03 (-0.12, 0.06)	0.05 (-0.04, 0.15)	-0.05 (-0.14, 0.04)	0.01 (-0.09, 0.11)	0.06 (-0.03, 0.15)	0.02 (-0.07, 0.10)
Emptying Fraction	Model 1	-0.04 (-0.12, 0.05)	-0.04 (-0.12, 0.04)	0.04 (-0.04, 0.12)	-0.01 (-0.10, 0.08)	-0.01 (-0.09, 0.07)	-0.04 (-0.12, 0.05)
	Model 2	-0.03 (-0.12, 0.05)	-0.05 (-0.14, 0.03)	0.01 (-0.07, 0.09)	-0.01 (-0.10, 0.08)	-0.01 (-0.10, 0.07)	-0.05 (-0.13, 0.03)
Peak Systolic Longitudinal Strain	Model 1	-0.01 (-0.09, 0.08)	-0.04 (-0.13, 0.04)	-0.03 (0.12, 0.05)	-0.06 (-0.16, 0.03)	-0.02 (-0.10, 0.06)	-0.03 (-0.11, 0.06)
	Model 2	-0.02 (-0.11, 0.06)	-0.05 (-0.14, 0.03)	-0.03 (-0.12, 0.05)	-0.10 (-0.19, 0.00)	-0.06 (-0.14, 0.03)	-0.06 (-0.14, 0.02)
Conduit Strain	Model 1	-0.03 (-0.11, 0.05)	0.00 (-0.08, 0.08)	0.04 (-0.12, 0.13)	0.01 (-0.08, 0.11)	0.00 (-0.08, 0.08)	-0.01 (-0.09, 0.07)
	Model 2	-0.04 (-0.13, 0.03)	-0.01 (-0.09, 0.07)	0.02 (-0.07, 0.10)	-0.02 (-0.11, 0.07)	-0.02 (-0.10, 0.06)	-0.03 (-0.11, 0.06)
Contractile Strain	Model 1	0.00 (-0.08, 0.08)	-0.06 (-0.14, 0.02)	-0.05 (-0.13, 0.03)	-0.08 (-0.17, 0.01)	-0.03 (-0.11, 0.05)	-0.02 (-0.09, 0.06)
	Model 2	-0.01 (-0.09, 0.07)	-0.06 (-0.14, 0.02)	-0.06 (-0.15, 0.02)	-0.11 (-0.20, -0.02)	-0.05 (-0.13, 0.03)	-0.05 (-0.13, 0.03)
Function Index	Model 1	-0.01 (-0.10, 0.07)	-0.04 (-0.13, 0.04)	0.00 (-0.08, 0.09)	-0.01 (-0.10, 0.09)	-0.03 (-0.11, 0.06)	-0.05 (0.13, 0.04)
	Model 2	-0.01 (-0.10, 0.08)	-0.04 (-0.12, 0.04)	0.05 (-0.04, 0.14)	-0.01 (0.10, 0.09)	-0.03 (-0.12, 0.05)	-0.05 (-0.13, 0.03)
Stiffness Index	Model 1	-0.06 (-0.14, 0.03)	0.00 (-0.09, 0.08)	-0.01 (-0.09, 0.08)	0.07 (-0.03, 0.17)	0.01 (-0.09, 0.07)	-0.01 (-0.09, 0.07)
	Model 2	-0.06 (-0.15, 0.03)	-0.01 (-0.09, 0.08)	0.01 (-0.08, 0.10)	0.09 (-0.01, 0.19)	0.07 (-0.01, 0.16)	0.02 (-0.06, 0.10)

Model 1: Adjusted by age, sex and site. Model 2: Adjusted by age, sex, site, number of people living in the household, employment status (yes or no), years of schooling, current smoking (yes or no) and former smoker (yes or no), METS per day of moderate to vigorous physical activity, Mediterranean diet 17-item score, body mass index, diagnosis of arrhythmia, diagnosis of diabetes, and diagnosis of depression at baseline. Values are standardized beta coefficients representing standard deviation change in cognitive function outcomes per a standard deviation increase in left atrial measurements.

Association of markers of left atrium structure and function with 2-year difference cognitive function scores among 468 participants of the PREDIMED-PLUS Trial

Table 4:

Left atrial measurements	Mini-mental examination	Semantic fluency	Phonetic fluency	Digits span total (n=358)	Trail Making Test A	Trail Making Test B
Volume Index	Model 1	0.00 (-0.09, -0.08)	0.03 (-0.06, 0.11)	0.01 (-0.07, 0.09)	-0.12 (-0.21, -0.02)	-0.06 (-0.13, 0.02)
	Model 2	-0.02 (-0.11, 0.06)	0.02 (-0.07, 0.10)	0.00 (-0.08, 0.08)	-0.12 (-0.22, 0.02)	-0.07 (-0.14, 0.01)
Emptying Fraction	Model 1	-0.02 (-0.09, 0.06)	0.01 (-0.06, 0.08)	-0.01 (-0.08, 0.06)	0.02 (-0.07, 0.11)	0.03 (-0.04, 0.09)
	Model 2	-0.00 (-0.08, 0.08)	0.02 (-0.06, 0.10)	0.00 (-0.07, 0.07)	0.03 (-0.06, 0.12)	0.04 (-0.03, 0.12)
Peak Systolic Longitudinal Strain	Model 1	-0.01 (-0.08, 0.07)	-0.04 (-0.12, 0.03)	0.08 (0.00, 0.15)	0.10 (0.01, 0.19)	0.04 (-0.03, 0.11)
	Model 2	0.00 (-0.08, 0.08)	-0.05 (-0.13, 0.03)	0.09 (0.00, 0.17)	0.11 (0.02, 0.20)	0.06 (-0.04, 0.13)
Conduit Strain	Model 1	-0.03 (-0.10, 0.02)	-0.10 (-0.17, -0.02)	0.04 (-0.04, 0.12)	0.06 (-0.03, 0.15)	0.05 (-0.02, 0.12)
	Model 2	-0.02 (-0.10, 0.06)	-0.09 (-0.17, -0.02)	0.03 (-0.04, 0.12)	0.07 (-0.03, 0.16)	0.06 (-0.02, 0.13)
Contractile Strain	Model 1	0.00 (-0.08, 0.08)	0.03 (-0.05, 0.10)	0.07 (-0.01, 0.14)	0.07 (-0.02, 0.16)	0.01 (-0.06, 0.08)
	Model 2	0.02 (-0.06, 0.10)	0.02 (-0.05, 0.10)	0.08 (0.00, 0.15)	0.08 (-0.01, 0.18)	0.03 (-0.05, 0.10)
Function Index	Model 1	-0.01 (-0.09, 0.07)	-0.02 (-0.10, 0.06)	0.00 (-0.07, 0.08)	0.07 (-0.03, 0.16)	0.05 (-0.02, 0.13)
	Model 2	0.01 (-0.07, 0.10)	-0.02 (-0.10, 0.07)	0.01 (-0.07, 0.09)	0.08 (-0.03, 0.17)	0.07 (-0.01, 0.14)
Stiffness Index	Model 1	0.03 (-0.05, 0.11)	0.02 (-0.06, 0.10)	0.00 (-0.08, 0.09)	-0.16 (-0.25, -0.07)	-0.02 (-0.09, 0.06)
	Model 2	0.01 (-0.07, 0.09)	0.03 (-0.06, 0.11)	-0.02 (-0.11, 0.07)	-0.19 (-0.29, -0.089)	-0.03 (-0.10, 0.05)

Model 1: Adjusted by age, sex, intervention arm, and site. Model 2: Adjusted by age, sex, intervention arm, site, number of people living in the household, employment status (yes or no), years of schooling, current smoking (yes or no) and former smoker (yes or no), METS per day of moderate to vigorous physical activity, Mediterranean diet 17-item score body mass index, diagnosis of arrhythmia, diagnosis of diabetes, and diagnosis of depression at baseline. Values are standardized beta coefficients representing standard deviation change in cognitive function outcomes per a standard deviation increase in left atrial measurements.